256,665 Shares in Krystal Biotech, Inc. $KRYS Bought by Jupiter Topco LLC

Jupiter Topco LLC bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the second quarter, HoldingsChannel.com reports. The firm bought 256,665 shares of the company’s stock, valued at approximately $95,387,000.

Other hedge funds also recently bought and sold shares of the company. Royal Bank of Canada lifted its position in Krystal Biotech by 145.2% in the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after purchasing an additional 964 shares during the period. AQR Capital Management LLC raised its stake in shares of Krystal Biotech by 29.9% during the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after buying an additional 2,792 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Krystal Biotech by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after acquiring an additional 688 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Krystal Biotech in the first quarter worth about $218,000. Finally, Cetera Investment Advisers raised its stake in shares of Krystal Biotech by 107.9% in the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock valued at $597,000 after purchasing an additional 2,255 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Stock Up 1.0%

NASDAQ KRYS opened at $359.76 on Thursday. The company has a market capitalization of $10.65 billion, a price-to-earnings ratio of 45.08 and a beta of 0.53. The stock has a fifty day simple moving average of $348.38 and a 200 day simple moving average of $303.24. Krystal Biotech, Inc. has a twelve month low of $136.73 and a twelve month high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The company had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Research analysts expect that Krystal Biotech, Inc. will post 7.68 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the transaction, the insider owned 1,378,155 shares in the company, valued at $424,623,337.05. The trade was a 1.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the transaction, the executive vice president owned 1,000 shares in the company, valued at $347,270. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 51,000 shares of company stock worth $16,278,020. Company insiders own 13.10% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on KRYS. TD Cowen boosted their target price on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. HC Wainwright lifted their price target on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research report on Tuesday, June 16th. Evercore reiterated an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 5th. Wall Street Zen downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Bank of America lifted their price target on shares of Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Krystal Biotech presently has a consensus rating of “Moderate Buy” and a consensus price target of $365.40.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.